Peroxisome proliferator-activated receptor ligands regulate lipid content, metabolism, and composition in fetal lungs of diabetic rats

M Kurtz1, E Capobianco1, V Careaga2, N Martinez1, M B Mazzuco1, M Maier2 and A Jawerbaum1

1Laboratory of Reproduction and Metabolism, CEFyBO-CONICET, School of Medicine and 2UMYMFOR (CONICET-UBA), Department of Organic Chemistry, School of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires, Argentina

Correspondence should be addressed to A Jawerbaum
Email a.jawerbaum@gmail.com

Abstract

Maternal diabetes impairs fetal lung development. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors relevant in lipid homeostasis and lung development. This study aims to evaluate the effect of in vivo activation of PPARs on lipid homeostasis in fetal lungs of diabetic rats. To this end, we studied lipid concentrations, expression of lipid metabolizing enzymes and fatty acid composition in fetal lungs of control and diabetic rats i) after injections of the fetuses with Leukotriene B4 (LTB4, PPARα ligand) or 15deoxyΔ12,14prostaglandin J2 (15dPGJ2, PPARγ ligand) and ii) fed during pregnancy with 6% olive oil- or 6% safflower oil-supplemented diets, enriched with PPAR ligands were studied. Maternal diabetes increased triglyceride concentrations and decreased expression of lipid-oxidizing enzymes in fetal lungs of diabetic rats, an expression further decreased by LTB4 and partially restored by 15dPGJ2 in lungs of male fetuses in the diabetic group. In lungs of female fetuses in the diabetic group, maternal diets enriched with olive oil increased triglyceride concentrations and fatty acid synthase expression, while those enriched with safflower oil increased triglyceride concentrations and fatty acid transporter expression. Both olive oil- and safflower oil-supplemented diets decreased cholesterol and cholesteryl ester concentrations and increased the expression of the reverse cholesterol transporter ATP-binding cassette A1 in fetal lungs of female fetuses of diabetic rats. In fetal lungs of control and diabetic rats, the proportion of polyunsaturated fatty acids increased with the maternal diets enriched with olive and safflower oils. Our results revealed important changes in lipid metabolism in fetal lungs of diabetic rats, and in the ability of PPAR ligands to modulate the composition of lipid species relevant in the lung during the perinatal period.

Key Words
- diabetes in pregnancy
- fetus
- PPAR
- lipids
- lung

Published by Bioscientifica Ltd.

Journal of Endocrinology
(2014) 220, 345–359
Introduction

Diabetes during pregnancy impairs fetal development, increases fetal morbidity and mortality, and leads to adverse consequences that are evident in the offspring during the perinatal and adult stages (Weindling 2009, Simeoni & Barker 2009, Ali & Dornhorst 2011). Both glucose and lipid metabolic substrates transferred in excess from maternal circulation into the fetuses have been involved in the generation of a proinflammatory environment that challenges the development of the fetal organs (Herrera & Ortega-Senovilla 2010, Lappas et al. 2011, Higa & Jawerbaum 2013). In the fetal lung, the effect of maternal diabetes is evidenced by structural alterations (Koskinen et al. 2012), delayed pulmonary maturation (Piper 2002), altered production of surfactant proteins and lipids (Bourbon & Farrell 1985, Trevino-Alanis et al. 2009), and increased pro-oxidative and proinflammatory pathways (Koskinen et al. 2010, Kurtz et al. 2012, Milla & Zirbes 2012).

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that regulate the expression of target genes involved in lipid homeostasis and in antioxidant and anti-inflammatory processes (Wahl & Michalik 2012). Endogenous PPAR ligands are certain lipids and lipid derivatives such as unsaturated fatty acids and eicosanoids, capable of activating one or more PPAR isoforms (Hihi et al. 2002). Indeed, the three PPAR isotypes, named PPARα, PPARγ, and PPARδ, can be activated by oleic acid, a monounsaturated fatty acid present in increased concentrations in olive oil, and by linoleic acid, a polyunsaturated fatty acid (PUFA) present in increased concentrations in safflower oil (Hihi et al. 2002). Linoleic acid is an essential fatty acid that leads to the formation of arachidonic acid, a substrate needed for the formation of prostaglandins and leukotrienes. 15-DeoxyΔ12,14-prostaglandin J2 (15dPGJ2) is an endogenous ligand of PPARγ that possesses potent anti-inflammatory effects (Scher & Pillinger 2005). Indeed, PPARγ activation can reduce nitric oxide production and matrix metalloproteinases overactivity, markers of a proinflammatory state, in different tissues, including the lung and the placenta (Jawerbaum et al. 2004, Pustovrh et al. 2009, Wagner et al. 2012). PPARγ is also involved in the differentiation of lipid-laden lung fibroblasts, cells that incorporate and accumulate lipids for further provision of lipids to the alveolar type II cells, which produce the surfactant lipids (Chen et al. 1998, Rehan & Torday 2012).

On the other hand, leukotriene B4 (LTB4) is an endogenous ligand of PPARα, a PPAR isotype clearly involved in the oxidation of lipids in metabolic tissues (Lefebvre et al. 2006, Narala et al. 2010). In diabetic pregnancies, PPARα activation negatively regulates lipid content in the fetal liver and the placenta (Martinez et al. 2011a,b). In a recent study, we have found that both administration of LTB4 to fetuses and maternal diets supplemented with 6% olive oil or 6% safflower oil (enriched in unsaturated fatty acids that activate the three PPAR isotypes) prevent overproduction of nitric oxide, an excess involved in the induction of a proinflammatory environment in the lungs of fetuses of diabetic rats (Kurtz et al. 2012). Indeed, these PPAR ligands provided by the enriched diets are efficiently transferred to the fetus from the maternal circulation and lead to the regulation of antioxidant, anti-inflammatory, and lipid metabolic pathways in the fetus and the placenta (Jawerbaum & Capobianco 2011, Martinez et al. 2012).

As lipid content and composition are relevant in the lung in the perinatal period and may be regulated by PPARs, the aims of this work were to analyze lipid content and PPARα and PPARγ concentrations in the lungs of fetuses of diabetic rats at term gestation, and address whether in vivo PPAR activation changes lipid content, expression of lipid transporters and metabolizing enzymes and fatty acid composition in the fetal lung. To this end, we addressed the effect of injections of the fetus with the PPARα ligand LTB4 and the PPARγ ligand 15dPGJ2 on the expression of lipid-oxidizing enzymes in the lungs of fetuses of control and diabetic rats and evaluated the effect of dietary maternal treatments enriched in either 6% olive oil or 6% safflower oil on lipid content and on the expression of different PPAR-targeted enzymes involved in lipid metabolism in the lungs of fetuses of control and diabetic rats. Studies were carried out in both male and female fetuses, considering the sex differences evidenced in maturation and signaling pathways in the lung and in lung perinatal diseases (Carey et al. 2007, Seaborn et al. 2010).

Materials and methods

Animals

Albino Wistar rats bred in our animal facility were provided with commercial rat chow (Asociación Cooperativa Argentina, Buenos Aires, Argentina) and allowed to feed ad libitum. To induce diabetes, at 2 days of age, neonates received injections of streptozotocin (90 mg/kg, s.c.; Sigma–Aldrich) diluted in citrate buffer (0.05 M, pH 4.5; Sigma–Aldrich), as described previously.
Lungs were explanted and preserved as described below. Injection on GD21, the animals were killed and the fetal surgery lasted less than 10 min and the animals were and the skin layer were independently sewn. The entire into the abdominal cavity and the abdominal muscle layer tration, the left uterine horn was carefully introduced into the abdominal cavity and the abdominal muscle layer confirmed the first day of pregnancy (gestational day 1 (GD1)). On this day, both control and diabetic animals were randomized into three different groups: Group 1, non-treated animals; Group 2, animals whose fetuses were treated in vivo with either the PPARγ ligand LTB₄ or the PPARγ ligand 15dPGJ₂; and Group 3, animals fed with diets supplemented with 6% olive oil or 6% safflower oil, enriched in natural PPAR activators, from GD1 to GD21.

In Group 1, control (n=9) and diabetic (n=9) female rats were killed on GD21 and the lungs were explanted and preserved as described later.

In Group 2, the fetuses were treated in vivo with LTB₄ or 15dPGJ₂ or with vehicle alone on GD19, GD20, and GD21, as described previously (Kurtz et al. 2012). For this purpose, on GD19, GD20, and GD21, the pregnant animals were anesthetized in a CO₂ chamber and a slight anesthesia was maintained with ether vapors. An abdominal incision was performed and the left horn of the uterus was exposed. The animals which had five to seven fetuses in their left uterine horn were used. The fetuses were numbered from the ovary and alternate fetuses received subcutaneous injections on their backs through the uterine wall of with i) LTB₄ (0.1 nmol/fetus dissolved in vehicle; Cayman Chemical Co., Ann Arbor, MI, USA) or vehicle (0.3 μl ethanol/fetus, dissolved in saline solution) (n=9 rats) and ii) with 15dPGJ₂ (2 nmol/fetus, dissolved in vehicle; Cayman Chemical Co.) or vehicle (0.3 μl ethanol/fetus, dissolved in saline solution) (n=9 rats). After administration, the left uterine horn was carefully introduced into the abdominal cavity and the abdominal muscle layer and the skin layer were independently sewn. The entire surgery lasted less than 10 min and the animals were completely recovered after 15 min. At 3 h after the last injection on GD21, the animals were killed and the fetal lungs were explanted and preserved as described below.

In Group 3, control and diabetic mothers were fed from GD1 to GD21, with diets enriched in unsaturated fatty acids that activate PPARs: 6% olive oil (354% enriched in oleic acid) and 6% safflower oil (226% enriched in linoleic acid) (n=9 in each experimental group), as previously described (Martinez et al. 2012). The composition of this diet is presented in Table 1. On GD21, animals were killed and the fetal lungs were explanted and preserved as described below.

In all groups, animals were killed through decapitation. Maternal and fetal blood was collected in heparinized tubes and plasma was preserved at −80°C. Under a stereomicroscope, the sex of fetuses was determined and their lungs were explanted. Lungs of male and female fetuses were randomly selected and either preserved at −80°C for further analysis of lipid content and fatty acid composition or preserved in RNA stabilization solution (RNAlater, Invitrogen) for further evaluation of the expression of enzymes and transporters involved in lipid metabolism.

### Blood and plasma measurements

Glycemic values were measured using Accu-Chek reagent strips and a glucometer Accu-Chek (Bayer Diagnostics) within blood obtained from the tail vein of the mothers.

Maternal and fetal glycemia and triglyceridemia were measured in plasma using an enzymatic colorimetric commercial kit (Wiener Lab., Rosario, Argentina). Plasma from all female and male fetuses in each litter was pooled for this analysis.

### Table 1 Composition of diet. Reprinted from Martinez N, Sosa M, Higa R, Fornes D, Capobianco E & Jawerbaum A 2012 Dietary treatments enriched in olive and safflower oils regulate seric and placental matrix metalloproteinases in maternal diabetes. Placenta 33 8–16, with permission from Elsevier

<table>
<thead>
<tr>
<th>Carbohydrates (g/100 g)</th>
<th>Standard diet</th>
<th>Standard diet supplemented with 6% olive oil</th>
<th>Standard diet supplemented with 6% safflower oil</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>48</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Proteins (g/100 g)</td>
<td>25</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>Fat (g/100 g)</td>
<td>5</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Calories (kcal %)</td>
<td>324</td>
<td>340</td>
<td>345</td>
</tr>
<tr>
<td>Major fatty acid content (g/100 g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C16:0 palmitic acid</td>
<td>0.58</td>
<td>1.55</td>
<td>0.97</td>
</tr>
<tr>
<td>C18:0 stearic acid</td>
<td>0.16</td>
<td>0.26</td>
<td>0.25</td>
</tr>
<tr>
<td>C18:1 oleic acid</td>
<td>1.27</td>
<td>5.77</td>
<td>1.81</td>
</tr>
<tr>
<td>C18:2 linoleic acid</td>
<td>1.99</td>
<td>2.41</td>
<td>6.49</td>
</tr>
<tr>
<td>C18:3 linolenic acid</td>
<td>0.73</td>
<td>0.57</td>
<td>0.55</td>
</tr>
</tbody>
</table>
Lipid content measurements

Lungs of one female and one male fetus from each rat group were each homogenized in 1000 µl PRS and protein content in the homogenates was measured by the Bradford assay. Tissue lipids were extracted from 500 µl of each homogenate by three rounds of organic extraction in methanol:chloroform (2:1), following the method of Bligh & Dyer, as previously performed (Martinez et al. 2011b). The lipids extracted (equivalent to 400 µg of protein) were developed by thin layer chromatography on 0.2 mm silica gel plates (Merck), using hexane:ether:acetic acid (80:20:2, v:v:v) as the developing solvent mixture. Lipid species were stained with iodine vapors, identified and quantified by comparison with known amounts of standards on the same plate, and analyzed densitometrically with the Image J Software (Bethesda, MD, USA).

Expression of enzymes and transporters involved in lipid metabolism

Lung RNA was extracted from one female and one male fetus from each rat group for the evaluation of gene expression of acyl CoA oxidase (ACO), carnitine palmitoyltransferase 1 (CPT1), fatty acid synthase (FAS), fatty acid transporter (FAT), and ATP-binding cassette A1 (ABCA1) by RT-PCR, a semiquantitative method, as previously determined (Kurtz et al. 2012). Fetal lung RNA was extracted with Tri reagent (Genbiotech, Buenos Aires, Argentina) in accordance with the manufacturer’s instructions. cDNA was synthesized by incubating 1 µg of extracted RNA in a first-strand buffer containing MMLV enzyme (Promega), random primer hexamers, and each of all four dNTPs (Invitrogen), in accordance with the MMLV manufacturer’s instructions. cDNA (2 µl) was used to perform the amplification in 25 µl reaction buffer containing dNTPs, magnesium chloride solution, Taq polymerase (GoTaq Polymerase; Promega), and each specific primer, in accordance with the Taq polymerase manufacturer’s instructions.

Primers for ACO were forward: 5'-CCACATGCAGCTTGTCTGG-3' and reverse: 5'-CTCTCCCAGCTGACTCTC-3', whose amplification product is a 363-bp fragment (Lillycrop et al. 2005). Primers for CPT1 were forward: 5'-TATCGTGGCTAGCGTCCAT-3' and reverse: 5'-CATCTGACCTCCTGCTTTGG-3', whose amplification product is a 215-bp fragment (Cheng et al. 2004). Primers for FAS were forward: 5'-CTTTGAGGTTCGGAGTTACCC-3' and reverse: 5'-GCCCTGGAAGGCAGTCTC-3', whose amplification product is a 163-bp fragment (Salas et al. 2007). Primers for FAT were forward: 5'-CTCAGGCCTTCTGACTTCC-3' and reverse: 5'-CACAGGCTTTCTCTTTGC-3', whose amplification product is a 214-bp fragment (designated using Primer 3 Software, http://bioinfo.ut.ee/primer3-0.4.0/primer3). Primers for ABCA1 were forward: 5'-CCACCTGAGGCTGACTTCTTGC-3' and reverse: 5'-GGCTCCAGAGTCCATGTT-3', whose amplification product is a 194-bp fragment (Kobayashi et al. 2011). The primers for the ribosomal protein L30, used as an internal control were forward: 5'-CCATCTGCGCGTCTGATCTT-3' and reverse: 5'-GGCG-AGGATAACCAATTTC-3', whose amplification product is a 201-bp fragment, (Primer 3 Software). The initial conditions for the reaction were 95 °C for 5 min, followed by 34 cycles for ACO, 34 cycles for CPT1, 32 cycles for FAS, 29 cycles for FAT, 28 cycles for ABCA1, and 25 cycles for L30. Each cycle consisted of denaturation at 95 °C for 15 s, primer annealing at 58 °C for 30 s, and extension at 72 °C for 15 s. The resulting products were separated on a 2% agarose gel and stained with syber safe (Invitrogen). The images were taken with an ImageQuant spectrophotometer (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and the density of the bands was quantified with the Image J Software and normalized to L30.

Fatty acid composition of tissue lipids

Fatty acid methyl esters (FAME) of lung lipids extracted from one female and one male fetus from each rat group were prepared by reaction with 5% HCl in methanol at 70 °C for 2 h. After cooling, water was added and FAME were extracted with chloroform. FAME were analyzed by gas chromatography–mass spectrometry on a Shimadzu GCMS-QP5050 A (Shimadzu Corporation, Kyoto, Japan) as previously described (Careaga et al. 2013). FAME were also analyzed by gas chromatography on a Thermo Focus CG chromatograph equipped with a flame ionization detector and a 25-m cross-linked methyl silicone fused silica capillary column (15 m × 0.25 mm internal diameter, 0.25 µm thickness; Agilent Corporation, Santa Clara, CA, USA). Nitrogen was the carrier gas. Both injector and detector temperatures were set at 280 °C. Column temperature was programmed to increase from 37 to 195 °C at a rate of 24 °C/min then remain stable at 195 °C for 1 min, then increase at a rate of 3 °C/min up to 205 °C and remain at this temperature for 1 min, then increase at a rate of 8 °C/min up to 230 °C/min and remain stable at 230 °C for 35 min. Individual components were identified using mass spectral data and by comparing retention time data with those obtained for authentic laboratory standards (Sigma–Aldrich Co.). Quantitation was performed by comparing the percentage area of each FAME peak on the chromatogram with that of the internal standard.
of known weight (nonadecanoate methyl ester; Sigma–Aldrich Co.) and expressed as percentage of total fatty acids.

**Immunohistochemistry**

PPARα and PPARγ immunolocalization was evaluated in lung sections from one female and one male fetus from each rat, as previously performed on other tissues (Capobianco et al. 2005). All sections were processed simultaneously under identical conditions. Briefly, lung tissues were fixed with 4% paraformaldehyde and then dehydrated and embedded in paraffin. Sections of 5 mm-thickness were deparaffinized and hydrated in xylene and a series of graded ethanol solutions. Antigen retrieval was performed by microwave heating these sections in trisodium citrate buffer and endogenous peroxidase was blocked with 0.3% 

**Statistical analysis**

Data are presented as the mean ± S.E.M. Groups were compared by Student’s t-test or two-way ANOVA in conjunction with Bonferroni’s test where appropriate. A P value <0.05 was considered statistically significant.

**Results**

**Maternal diabetes leads to lipid overaccumulation and altered PPARα and PPARγ concentrations in the fetal lung**

Maternal diabetes led to increases in glycemia in both the mothers (control, 93 ± 7 and diabetic, 215 ± 23 mg/dl; P<0.001) and the fetuses (fetuses of control mothers, 46±4 and fetuses of diabetic mothers, 147±10 mg/dl; P<0.001). Also triglyceridemia was increased in both the mothers (control, 2.1±0.3 and diabetic, 4.1±0.3 g/l; P<0.01) and the fetuses (fetuses of control mothers, 0.53±0.07 and fetuses of diabetic mothers, 0.90±0.07 g/l; P<0.01). These data correspond to all male and female fetuses of control (n=9) and diabetic (n=9) rats as no sex differences were observed.

The analysis of fetal lung lipid concentrations showed increased triglyceride concentrations (P<0.01) and no changes in the concentrations of phospholipids, cholesterol, and cholesteryl esters in lungs of female fetuses in the diabetic group compared with controls, and increased triglyceride (P<0.001) and phospholipid (P<0.05) concentrations and no changes in cholesterol and cholesteryl esters concentrations in the lungs of male fetuses in the diabetic group when compared with controls (Fig. 1A). Together with these changes, decreased expression of ACO and CPT1, rate-limiting enzymes in lipid oxidation, was observed in the lungs of both female and male fetuses in the diabetic groups (P<0.05) when compared with the respective control groups (Fig. 1B and C).

The analysis of PPARs showed that PPARα concentrations were similar in the lungs of female fetuses and reduced in the lungs of male fetuses in the diabetic group when compared with controls (Fig. 1D, lungs of female fetuses of control mothers: 1±0.19, n=5; lungs of female fetuses of diabetic mothers: 1.29±0.09, n=5; lungs of male fetuses of control mothers: 0.9±0.14, n=5; and lungs of male fetuses of diabetic mothers: 0.47±0.02, n=5; P<0.05). Similarly, PPARγ concentrations were similar in the lungs of female fetuses and reduced in the lungs of male fetuses in the diabetic group when compared with controls (Fig. 1E, lungs of female fetuses of control mothers: 1±0.34, n=5; lungs of female fetuses of diabetic mothers: 1.37±0.46, n=5; lungs of male fetuses of control mothers: 1.19±0.12, n=5; and lungs of male fetuses of diabetic mothers: 0.48±0.11, n=5; P<0.01).

**Effect of fetal administration of PPAR ligands on the expression of rate-limiting enzymes in lipid oxidation**

Considering the well-known function of PPARα in the regulation of lipid-oxidizing enzymes in different tissues (Desvergne et al. 2006, Lefebvre et al. 2006) and the decrease in lipid-oxidizing enzymes and overaccumulation of lipids observed in the lungs of fetuses of diabetic rats, we analyzed the in vivo effects of fetal PPARα activation on the expression of ACO and CPT1 in the lungs of female
Figure 1
(A) Lipid concentrations, (B) ACO expression, and (C) CPT1 expression in lungs of fetuses of control and diabetic rats. Values represent mean ± S.E.M., obtained from one female or one male fetus from each pregnant rat, n = 9 rats in each experimental group. Student's t-test was performed. Different letters denote significant differences between groups, P < 0.05.

(D) Representative photomicrographs of PPARα (original magnification, 400×) immunodetected with specific anti-PPARα antibody in lungs of fetuses of control and diabetic rats. (E) Representative photomicrographs of PPARγ (original magnification, 400×) immunodetected with specific anti-PPARγ antibody in lungs of fetuses of control and diabetic rats.
and male fetuses of control and diabetic mothers. For this purpose, fetuses from control and diabetic rats received injections of either LTB4 (0.1 nmol) or vehicle through the uterine wall on GD19, GD20, and GD21, and the fetal plasma and lungs were evaluated on GD21. Glycemia and triglyceridemia were increased in the diabetic fetuses that received LTB4 when compared with the control fetuses that received the same treatment ((glycemia: 15dPGJ2-treated fetuses of control mothers, 53 ± 11 and 15dPGJ2-treated fetuses of diabetic mothers, 158 ± 12 mg/dl; P < 0.001) and (triglyceridemia: 15dPGJ2-treated fetuses of control mothers, 0.61 ± 0.05 and 15dPGJ2-treated of from diabetic mothers, 0.75 ± 0.03 g/l; P < 0.05)). These data correspond to all male and female fetuses in each experimental group, obtained from control (n = 9) and diabetic (n = 9) rats, as no sex differences were observed. Fetal administration of 15dPGJ2 on late gestation induced no changes in ACO or CPT1 expression in the lungs of either female or male fetuses in the control group and in the lungs of female fetuses in the diabetic group. In contrast, fetal administration of 15dPGJ2 induced an increase in ACO and CPT1 expression in the lungs of male fetuses in the diabetic group (P < 0.05; Fig. 3).

Considering that PPARγ regulation of ACO and CPT1 in the fetal lung is different from that of metabolic tissues such as the liver and the heart (Desvergne et al. 2006, Lefebvre et al. 2006), we further addressed the ability of the PPARγ ligand 15dPGJ2 to regulate the expression of the evaluated enzymes involved in lipid oxidation. For this purpose, fetuses from control and diabetic rats received injections of either 15dPGJ2 (2 nmol) or vehicle through the uterine wall on GD19, GD20, and GD21, for further evaluation of fetal plasma and lungs on GD21. Glycemia and triglyceridemia were increased in the diabetic fetuses that received 15dPGJ2 when compared with the control fetuses that received the same treatment ((glycemia: 15dPGJ2-treated fetuses of control mothers, 53 ± 11 and 15dPGJ2-treated fetuses of diabetic mothers, 158 ± 12 mg/dl; P < 0.001) and (triglyceridemia: 15dPGJ2-treated fetuses of control mothers, 0.61 ± 0.05 and 15dPGJ2-treated of from diabetic mothers, 0.75 ± 0.03 g/l; P < 0.05)). These data correspond to all male and female fetuses in each experimental group, obtained from control (n = 9) and diabetic (n = 9) rats, as no sex differences were observed. Fetal administration of 15dPGJ2 on late gestation induced no changes in ACO or CPT1 expression in the lungs of either female or male fetuses in the control group and in the lungs of female fetuses in the diabetic group. In contrast, fetal administration of 15dPGJ2 induced an increase in ACO and CPT1 expression in the lungs of male fetuses in the diabetic group (P < 0.05; Fig. 3).

Figure 2
(A) ACO expression and (B) CPT1 expression in lungs of fetuses that had received injections of the PPARγ agonist LTB4 or of vehicle. Values represent mean ± S.E.M., obtained from one female or one male fetus from each pregnant rat, n = 9 rats in each experimental group. Two-way ANOVA in conjunction with Bonferroni’s test was performed. Different letters denote significant differences between groups, P < 0.05.

Figure 3
(A) ACO expression and (B) CPT1 expression in lungs of fetuses that had received injections of the PPARγ agonist 15dPGJ2 or of vehicle. Values represent mean ± S.E.M., obtained from one female or one male fetus from each pregnant rat, n = 9 rats in each experimental group. Two-way ANOVA in conjunction with Bonferroni’s test was performed. Different letters denote significant differences between groups, P < 0.05.
Effect of maternal diets enriched in PPAR ligands on lipid concentrations

Our previous studies have demonstrated the effects of dietary activation of PPARs on maternal diabetes in different fetal organs (Jawerbaum & Capobianco 2011, Martinez et al. 2011b) and the ability of these diets to reach the fetal lungs and regulate the expression of PPARs (Kurtz et al. 2012). Thus, we analyzed lipid composition and the expression of enzymes/transporters involved in lipid metabolism in the lungs of fetuses of control and diabetic rats fed with a 6% olive-oil-supplemented diet (354% enriched in oleic acid) or a 6% safflower-oil-supplemented diet (226% enriched in linoleic acid) during pregnancy (GD1–GD21).

Neither the 6% olive-oil- nor the 6% safflower-oil-supplemented diets changed fetal glycemia and triglyceridemia in control and diabetic experimental groups when compared with their respective groups fed the standard diet (control rats: glycemia (mg/dl): fetuses of control rats fed: i) the standard diet 0.58, ii) the 6% olive-oil-supplemented diet 0.59, and iii) the 6% safflower-oil-supplemented diet 0.60; triglyceridemia (g/l): fetuses of control rats fed: i) the standard diet 1.01, ii) the 6% olive-oil-supplemented diet 1.10, and iii) the 6% safflower-oil-supplemented diet 1.05). These data correspond to all male and female fetuses (n=9 rats in each experimental group) as no sex differences were observed. When we analyzed lipid concentrations in the lungs of female and male fetuses of control rats, we found that the maternal supplementation with either the 6% olive-oil- or the 6% safflower-oil-supplemented diets did not change the concentrations of the lipids evaluated when compared with the respective control groups fed the standard diet (Fig. 4). In contrast, in the lungs of female fetuses in the diabetic group, triglyceride concentrations were increased (P<0.05), and cholesterol and cholesteryl esters decreased (P<0.05) when the dams were fed with either the 6% olive-oil- or the 6% safflower-oil-supplemented diets and related to the diabetic group fed the standard diet (Fig. 4). On the other hand, in the lungs of male fetuses in the diabetic group, the only change observed was an increase in phospholipids when the dams were fed the 6% olive-oil-supplemented diet and compared with the diabetic group fed the standard diet (P<0.05; Fig. 4).

### Figure 4
Lipid concentrations in lungs of fetuses of control and diabetic rats fed with a 6% olive-oil- or a 6% safflower-oil-supplemented diet during pregnancy. Values represent mean ± S.E.M., obtained from one female or one male fetus from each pregnant rat, n=9 rats in each experimental group. Two-way ANOVA in conjunction with Bonferroni’s test was performed. Different letters denote significant differences between groups, P<0.05.
Effect of maternal diets enriched in PPAR ligands on the expression of enzymes/transporters involved in lipid metabolism

Considering the changes evidenced in lipid concentrations in lungs of fetuses of diabetic rats fed with the diets enriched in fatty acids that activate PPARs, and the well-known ability of PPARs to regulate different enzymes and transporters involved in the synthesis and transport of lipids (Desvergne et al. 2006), we analyzed the expression of FAS, FAT, and ABCA1 in lungs of fetuses of control and diabetic rats fed with a 6% olive-oil- or a 6% safflower-oil-supplemented diet during pregnancy.

FAS expression was unchanged in lungs of female and male fetuses in the diabetic group fed the standard diet when compared with their respective controls fed the same diet (Fig. 5A). In the control group, FAS expression was unchanged in lungs of female and male fetuses when

**Figure 5**
(A) FAS expression, (B) FAT expression, and (C) ABCA1 expression in lungs of fetuses of control and diabetic rats fed with a 6% olive-oil- or a 6% safflower-oil-supplemented diet during pregnancy. Values represent mean ± S.E.M., obtained from one female or one male fetus from each pregnant rat, n = 9 rats in each experimental group. Two-way ANOVA in conjunction with Bonferroni's test was performed. Different letters denote significant differences between groups, P < 0.05.
the animals fed either the 6% olive-oil- or the 6% safflower-oil-supplemented diets were compared with control animals fed the standard diet (Fig. 5A). FAS expression was increased in lungs of female fetuses (P<0.05), but unchanged in lungs of male fetuses in the diabetic group fed the 6% olive-oil-supplemented diet when compared with the diabetic group fed the standard diet (Fig. 5A). FAS expression was also unchanged in lungs of female and male fetuses in the diabetic group fed the 6% safflower-oil-supplemented diet when compared with the diabetic animals fed the standard diet (Fig. 5A).

FAT expression was decreased in lungs of both female and male fetuses in the diabetic group fed the standard diet when compared with their respective controls fed the same diet (P<0.05; Fig. 5B). FAT expression was unchanged in lungs of female fetuses in both the control and diabetic groups fed the 6% olive-oil-supplemented diet when compared with their respective controls fed the standard diet. However, FAT expression was increased in lungs of female fetuses in both the control and diabetic groups fed the 6% safflower-oil-supplemented diet when respectively compared with the control and diabetic groups fed the standard diet (P<0.05; Fig. 5B). FAT expression was unchanged in lungs of male fetuses in both control and diabetic groups fed either the olive-oil- or the safflower-oil-supplemented diets when respectively compared with the control and diabetic groups fed the standard diet (Fig. 5B).

ABCA1 expression was unchanged in lungs of female and male fetuses in the diabetic group fed the standard diet when compared with the control group fed the same diet (Fig. 5C). In the control group, ABCA1 expression was unchanged in lungs of female and male fetuses of rats fed either the 6% olive-oil- or the 6% safflower-oil-supplemented diets when compared with the control group fed the standard diet (Fig. 5C). However, in the diabetic group, both the 6% olive-oil- and the 6% safflower-oil-supplemented diets led to an increase in ABCA1 expression in lungs of female fetuses (P<0.05), although not in lungs of male fetuses when compared with the diabetic groups fed the standard diet (Fig. 5C).

**Table 2** Fatty acid composition in lungs of fetuses of control and diabetic rats fed with a 6% olive-oil- or 6% safflower-oil-supplemented diet during pregnancy. Values represent mean±S.E.M. Combined data of one female and one male fetus from each pregnant rat, n=6 rats in each experimental group. Two-way ANOVA in conjunction with Bonferroni’s test was performed.

<table>
<thead>
<tr>
<th>Fatty acid composition</th>
<th>Control Standard diet</th>
<th>Standard diet supplemented with 6% olive oil</th>
<th>Standard diet supplemented with 6% safflower oil</th>
<th>Diabetic Standard diet</th>
<th>Standard diet supplemented with 6% olive oil</th>
<th>Standard diet supplemented with 6% safflower oil</th>
</tr>
</thead>
<tbody>
<tr>
<td>C14:0 myristic acid</td>
<td>1.94±0.24a</td>
<td>1.66±0.33a</td>
<td>2.24±0.06a</td>
<td>2.06±0.21a</td>
<td>2.05±0.09a</td>
<td>1.94±0.10a</td>
</tr>
<tr>
<td>C15:0 pentadecanoic acid</td>
<td>1.23±0.288</td>
<td>0.38±0.03b</td>
<td>0.42±0.05b</td>
<td>0.40±0.04b</td>
<td>0.49±0.10b</td>
<td>0.51±0.05b</td>
</tr>
<tr>
<td>C16:0 palmitic acid</td>
<td>32.19±0.56a</td>
<td>31.78±0.61a</td>
<td>32.48±0.66a</td>
<td>33.50±0.18b</td>
<td>31.82±0.69b</td>
<td>31.52±0.39b</td>
</tr>
<tr>
<td>C17:0 margaric acid</td>
<td>0.37±0.07b</td>
<td>0.18±0.02b</td>
<td>0.19±0.03b</td>
<td>0.23±0.04b</td>
<td>0.21±0.04b</td>
<td>0.23±0.04b</td>
</tr>
<tr>
<td>C18:0 stearic acid</td>
<td>11.35±0.16b</td>
<td>11.69±0.40a</td>
<td>12.06±0.31a</td>
<td>11.18±0.386a</td>
<td>11.63±0.42a</td>
<td>12.59±0.31a</td>
</tr>
<tr>
<td>C20:0 arachid acid</td>
<td>0.36±0.03b</td>
<td>0.37±0.02b</td>
<td>0.38±0.04a</td>
<td>0.39±0.03a</td>
<td>0.38±0.16a</td>
<td>0.39±0.16a</td>
</tr>
<tr>
<td>C22:0 behenic acid</td>
<td>1.73±0.05a</td>
<td>1.83±0.07a</td>
<td>2.03±0.07a</td>
<td>1.63±0.20a</td>
<td>1.94±0.08a</td>
<td>2.38±0.10b</td>
</tr>
<tr>
<td>C16:1 palmitedoleic acid</td>
<td>6.58±0.37a</td>
<td>6.31±0.26a</td>
<td>5.98±0.29a</td>
<td>5.56±0.33ab</td>
<td>4.97±0.28b</td>
<td>4.42±0.33b</td>
</tr>
<tr>
<td>C18:1 oleic acid (n-9)</td>
<td>17.33±0.30a</td>
<td>17.68±0.32a</td>
<td>15.78±0.28a</td>
<td>20.19±3.7a</td>
<td>17.74±0.03a</td>
<td>15.63±0.53a</td>
</tr>
<tr>
<td>C20:1 gondoic acid (n-9)</td>
<td>0.41±0.05a</td>
<td>0.39±0.03a</td>
<td>0.30±0.02a</td>
<td>0.40±0.05a</td>
<td>0.38±0.03a</td>
<td>0.34±0.02a</td>
</tr>
<tr>
<td>C22:1 erucic acid (n-9)</td>
<td>0.67±0.07a</td>
<td>0.86±0.05a</td>
<td>0.91±0.04b</td>
<td>0.69±0.08a</td>
<td>0.46±0.03a</td>
<td>0.57±0.03a</td>
</tr>
<tr>
<td>C18:2 linoleic acid (n-6)</td>
<td>4.85±0.30a</td>
<td>5.09±0.09a</td>
<td>7.10±0.42b</td>
<td>5.09±0.60a</td>
<td>7.74±0.20a</td>
<td>8.24±0.50b</td>
</tr>
<tr>
<td>C20:2 eicosadienoic acid (n-3/n-6)</td>
<td>0.56±0.04a</td>
<td>0.62±0.07b</td>
<td>0.59±0.02a</td>
<td>0.53±0.06a</td>
<td>0.65±0.03a</td>
<td>0.68±0.05a</td>
</tr>
<tr>
<td>C20:3 docosahexaenoic acid (n-6)</td>
<td>0.36±0.04a</td>
<td>0.45±0.03a</td>
<td>0.54±0.02b</td>
<td>0.37±0.05a</td>
<td>0.56±0.04a</td>
<td>0.63±0.05b</td>
</tr>
<tr>
<td>ABCA1 expression</td>
<td>3.70±0.50a</td>
<td>11.61±0.37a</td>
<td>11.37±0.39b</td>
<td>10.49±0.29a</td>
<td>10.42±0.42a</td>
<td>11.85±0.12b</td>
</tr>
</tbody>
</table>

Different letters denote significant differences between groups, P<0.05.
rats fed either the 6% olive-oil- or the 6% safflower-oil-supplemented diets. No sex-dependent effects were observed on this parameter in the experimental groups evaluated, thus Table 2 shows the combined female and male data. In the animals fed the standard diet, only a decrease in pentadecanoic acid was observed in lungs of fetuses from diabetic rats when compared with the control group ($P<0.01$; Table 2). In lungs of fetuses of control animals, supplementation of the maternal diet with 6% olive oil led to a decrease in pentadecanoic acid and margaric acid and an increase in erucic acid and arachidonic acid when compared with the control group fed the standard diet ($P<0.05$; Table 2). In lungs of fetuses of control animals, supplementation of the maternal diet with 6% safflower oil led to a decrease in pentadecanoic acid and margaric acid and to an increase in behenic acid, erucic acid, linoleic acid, dihomo-gamma linolenic acid, and arachidonic acid when compared with the control group fed the standard diet ($P<0.01$; Table 2). In lungs of fetuses of diabetic animals, supplementation of the diet with 6% olive oil led to a decrease in erucic acid and to an increase in the PUFAs linoleic acid, dihomo-gamma linolenic acid, and docosapentaenoic acid when compared with the diabetic group fed the standard diet ($P<0.01$; Table 2). Also, in lungs of fetuses of diabetic animals, supplementation of the maternal diet with 6% safflower oil led to a decrease in palmitoleic acid and to increases in behenic acid, linoleic acid, dihomo-gamma linolenic acid, arachidonic acid, and docosapentaenoic acid ($P<0.01$; Table 2).

**Discussion**

The findings of this work demonstrate that maternal diabetes leads to an overaccumulation of lipid species and alters PPARx and PPARγ concentrations in the fetal lung in a sex-dependent manner. Moreover, these studies provide evidence that PPAR activators regulate the expression of lipid transporters and enzymes involved in lipid oxidation which synthesis, which leads to changes in lipid composition and fatty acid content in the fetal lung.

In humans, the lung can be affected by diabetic disease in both the child and the adult, and by maternal diabetes in the fetus (Milla & Zirbes 2012). Infants born to diabetic mothers are at increased risk of perinatal asphyxia, respiratory distress syndrome, pneumonia, and impaired cardiopulmonary adaptations (Robert et al. 1976, Vela-Huerta et al. 2007, Milla & Zirbes 2012). Relevant roles for PPARs have been identified in the maturation and regulation of proinflammatory mediators in the lung (Belvisi & Hele 2008, Rehan & Torday 2012). Sex differences in maturation and signaling pathways in lung tissues as well as in lung perinatal diseases have been observed (Carey et al. 2007, Seaborn et al. 2010). Also, poorer perinatal outcome has been reported in male newborns of women with pregestational diabetes (Garcia-Patterson et al. 2011).

In this work, we evaluated a mild diabetic rat model and found increased concentrations of triglycerides in the lungs of female fetuses and of triglycerides and phospholipids in the lungs of male fetuses, indicating that in both sexes, the fetal lung is a target organ that accumulates excessive metabolic substrates in maternal diabetes. There is strong evidence of diabetes-induced changes in lipid metabolism, sex-dependent changes in lipid metabolic pathways, and of the role of estrogens in lipid metabolism (Kautzky-Willer & Handisurya 2009, Benz et al. 2012, Oosthuyse & Bosch 2012). Also estrogen-responsive elements are found in PPARs promoters, and estrogens can regulate PPARs expression and activation (Yoon 2009, Oosthuyse & Bosch 2012). In this regard, we found in this work that maternal diabetes induces a decrease in PPARx and PPARγ concentrations only in the lungs of male fetuses. Previous research performed using this experimental model has shown that at term gestation, maternal diabetes increases the fetal weight and the fetal lung weight, induces no changes in fetal lung: fetal weight ratio, and increases markers of an oxidative and proinflammatory environment in fetal lungs and other fetal organs (Jawerbaum & Capobianco 2011, Kurtz et al. 2012).

Several studies have shown that maternal diabetes leads to increases in the transfer of glucose and other metabolites, which result in excessive metabolic substrates in the fetal circulation and in the fetal liver (Herrera et al. 2006, Martinez et al. 2011b). Possibly, the increased lipids in the lung during maternal diabetes are the result of their efficient uptake from the maternal circulation that sustains the production of surfactant lipids at term gestation (Rooney et al. 1994). Also, we observed a decrease in the expression of the lipid-oxidizing enzymes ACO and CPT1 in lungs of female and male fetuses from diabetic rats. ACO and CPT1 are rate-limiting enzymes in peroxisomal and mitochondrial lipid oxidation, respectively, and clear targets of PPARx activation in the liver, a signaling pathway relevant in the oxidation of fuels in the fasting state (Desvergne et al. 2006). Besides, PPARx has been shown to reduce inflammation and vascular leakage in experimental models of acute lung injury, inflammation, and asthma (Becker et al. 2006, Belvisi & Hele 2008, Schaefer et al. 2008).
In this study, no changes in the serum parameters evaluated were found when fetuses from control and diabetic animals received injections of the PPAR agonists LTB4 or 15dPGJ2 compared with their respective groups that received injections of vehicle, showing values similar to those, respectively, found in control and diabetic rats in the untreated groups. On the other hand, these PPAR agonist treatments led to changes in the expression of lipid-oxidizing enzymes in the fetal lung. Indeed, the PPARα activator LTB4 negatively regulates the expression of ACO and CPT1, indicating that PPARα regulates the expression of limiting lipid-oxidizing enzymes in a way opposite to that observed in other adult and developing organs such as the liver (Desvergne et al. 2006, Martinez et al. 2011b, Capobianco et al. 2013). Further research to clarify the nature of these differences should be of value.

On the other hand, we found that in the lungs of male fetuses from diabetic rats, the PPARγ activator 15dPGJ2 positively regulates the expression of ACO and CPT1, and partially restores the expression of these oxidizing enzymes to values observed in control tissues. Activation of PPARγ has been found to ameliorate lung proinflammatory processes in endotoxemic inflammation and prevent asthma induced by nicotine exposure in rat offspring (Liu et al. 2011, Reddy et al. 2012). During fetal lung development, PPARγ regulates the differentiation of lipid-laden fibroblasts, cells that take up circulating lipids, accumulate triglycerides, and transfer them to provide the lipid substrates needed for the production of surfactant lipids in type II alveolar cells (Rehan & Torday 2012). Previous studies have shown the ability of diets enriched in PUFAs to protect rat neonates from oxygen toxicity (Sosenko et al. 1988), prevent pneumonia in adult mice (Sharma et al. 2013), reduce the occurrence of bronchopulmonary dysplasia in newborn babies (Rudiger et al. 2000), increase PUFAs concentrations in neonatal lungs in baboons (Chao et al. 2003), and reduce nitric oxide overproduction in fetal lungs in diabetic rats (Kurtz et al. 2012).

In this work, we found that diets enriched with either 6% olive oil or 6% safflower oil increased triglyceride concentrations in the lungs of female fetuses of diabetic rats, and that diets enriched with 6% olive oil increased phospholipid concentrations in the lungs of male fetuses of diabetic rats when compared with those of diabetic rats fed the standard diet. The concomitant increase in PPAR target genes involved in lipid synthesis (FAS) or transport (FAT) in lungs of female fetuses of diabetic rats fed the 6% olive-oil- or the 6% safflower-oil-supplemented diets indicates that this increase may contribute to the accumulation of triglycerides and to providing lipid substrates needed for the production of surfactant lipids in these experimental groups (Rehan & Torday 2012). The sex differences observed can be explained by the complex effects of estrogens, which induce profound changes in lipid metabolic pathways and regulate PPARs expression, and of androgens, which induce changes in the expression of multiple genes, including several PPAR coactivators and corepressors (Bresson et al. 2010, Benz et al. 2012, Oosthuysse & Bosch 2012).

On the other hand, we observed a decrease in cholesterol and cholesteryl ester concentrations in the lungs of female fetuses in the diabetic group fed the evaluated diets enriched in PPAR ligands, which may be related to the increased expression of the reverse cholesterol transporter ABCA1 observed in the same experimental groups. Reduced cholesterol concentrations probably increase membrane fluidity and facilitate cell signaling, indicating possible beneficial effects in lungs of fetuses from diabetic rats, a point that deserves further research. In addition, it should be noted that although the unsaturated fatty acids provided by the oil-supplemented diets evaluated can both activate PPARs and serve as substrates for the synthesis of other PPAR activators, endogenous PPAR ligands can also have PPAR-independent effects (Luconi et al. 2010, Wahlì & Michalik 2012). Also, although only minor changes were detected in fatty acid composition in the fetal lungs of the diabetic group when compared with the controls, an important increase in PUFAs was found in the diabetic group fed the 6% olive-oil- and the 6% safflower-oil-supplemented diets when compared with the diabetic group fed the standard diet.

Previous studies have shown that supplementation of diets with PUFAs increases lung concentrations of PUFAs, indicating their efficient transfer from the maternal diet to the lung (Sosenko et al. 1991, Chao et al. 2003). Our results indicate that these changes, which can help to protect the lung function during the perinatal period, can be achieved in maternal diabetes as efficiently as in the control mothers. The 6% safflower-oil-supplemented diet provides linoleic acid, an essential fatty acid that is the substrate for the production of other n-6 PUFAs that are increased in lungs of fetuses of the rats fed both diets enriched in unsaturated fatty acids. Interestingly, although the 6% olive-oil-supplemented diet is mostly enriched in oleic acid, which cannot be metabolized into PUFAs in animals, both n-6 and n-3 PUFAs are increased in lungs of fetuses of rats fed this supplemented diet.
Thus, possibly, an antioxidant function of the olive-oil-supplemented diet, which deserves to be further studied and may be exerted both through its high content of polyphenols and through the antioxidant effect of PPARs activation, may help to preserve PUFAs in the fetal lung. This may constitute a relevant function in diabetic pregnancies, in which the loss of PUFAs due to peroxidation is a relevant problem that leads to the loss of many bioactive lipids, including those that activate PPARs (Jawerbaum & Gonzalez 2006, Negre-Salvayre et al. 2010).

In conclusion, increased lipid content and few changes in fatty acid composition are observed in the fetal lung at term in the mild diabetic rat model evaluated. In vivo administration of PPAR ligands led to changes in lipid content, in the expression of lipid transporters and enzymes involved in lipid oxidation and synthesis, and in the proportion of PUFAs in lungs of fetuses of diabetic rats, possibly providing a local activation of PPARs that may help the lungs to accomplish their complex functions in the perinatal period in maternal diabetes.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica de Argentina (grant number PICT 2010-00034) and by the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET; grant number PIP 11220100100002). E C, N M, M B M, and A J are research members of CONICET.

Acknowledgements
The authors thank Vet. Marcela Márquez and Tech. Enzo Cuba for the valuable help with animal handling.

References

Capobianco E, Jawerbaum A, Romanini MC, White V, Pustovrh C, Higa R, Martinez N, Mugnaini MT, Sonez C & Gonzalez E 2005 15-Deoxy-
A12,14-prostaglandin J2 and peroxisome proliferator-activated receptor γ (PPARs) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPAR agonist on nitridergic and lipid placental metabolism. Reproduction, Fertility, and Development 17 423–433. (doi:10.1071/RD04067)
Chen H, Jackson S, Doro M & McGowan S 1998 Perinatal expression of enzymes involved in lipid oxidation and synthesis, and in the proportion of PUFAs in lungs of fetuses of diabetic rats, possibly providing a local activation of PPARs that may help the lungs to accomplish their complex functions in the perinatal period in maternal diabetes.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica de Argentina (grant number PICT 2010-00034) and by the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET; grant number PIP 11220100100002). E C, N M, M B M, and A J are research members of CONICET.

Acknowledgements
The authors thank Vet. Marcela Márquez and Tech. Enzo Cuba for the valuable help with animal handling.

REFERENCES
Capobianco E, Jawerbaum A, Romanini MC, White V, Pustovrh C, Higa R, Martinez N, Mugnaini MT, Sonez C & Gonzalez E 2005 15-Deoxy-
A12,14-prostaglandin J2 and peroxisome proliferator-activated receptor γ (PPARs) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPAR agonist on nitridergic and lipid placental metabolism. Reproduction, Fertility, and Development 17 423–433. (doi:10.1071/RD04067)


Yoon M 2009 The role of PPARs in lipid metabolism and obesity: focusing on the effects of estrogen on PPARα actions. *Pharmacological Research* **60** 151–159. (doi:10.1016/j.phrs.2009.02.004)

Received in final form 13 December 2013
Accepted 2 January 2014
Accepted Preprint published online 3 January 2014